Latest Insider Transactions at Quest Diagnostics Inc (DGX)
This section provides a real-time view of insider transactions for Quest Diagnostics Inc (DGX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of QUEST DIAGNOSTICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of QUEST DIAGNOSTICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 06
2023
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Grant, award, or other acquisition
|
Direct |
9,917
+11.32%
|
$1,457,799
$147.86 P/Share
|
|
Mar 06
2023
|
Stephen H Rusckowski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
38,604
-9.02%
|
$5,674,788
$147.86 P/Share
|
|
Mar 06
2023
|
Stephen H Rusckowski Director |
BUY
Grant, award, or other acquisition
|
Direct |
82,631
+16.18%
|
$12,146,757
$147.86 P/Share
|
|
Mar 06
2023
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
8,036
-7.26%
|
$1,181,292
$147.86 P/Share
|
|
Mar 06
2023
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
15,204
+12.08%
|
$2,234,988
$147.86 P/Share
|
|
Mar 06
2023
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
583
-4.93%
|
$85,701
$147.86 P/Share
|
|
Mar 06
2023
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
1,985
+14.37%
|
$291,795
$147.86 P/Share
|
|
Mar 03
2023
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
717
-1.05%
|
$100,380
$140.63 P/Share
|
|
Mar 02
2023
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
593
-1.52%
|
$81,834
$138.54 P/Share
|
|
Mar 01
2023
|
Stephen H Rusckowski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,496
-1.0%
|
$489,440
$140.69 P/Share
|
|
Mar 01
2023
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
320
-0.81%
|
$44,800
$140.69 P/Share
|
|
Mar 01
2023
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
90
-0.84%
|
$12,600
$140.69 P/Share
|
|
Mar 01
2023
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,292
-1.34%
|
$180,880
$140.69 P/Share
|
|
Mar 01
2023
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
392
-0.57%
|
$54,880
$140.69 P/Share
|
|
Mar 01
2023
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
65
-0.66%
|
$9,100
$140.69 P/Share
|
|
Mar 01
2023
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
68
-0.21%
|
$9,520
$140.69 P/Share
|
|
Feb 24
2023
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
1,415
-3.46%
|
$199,515
$141.42 P/Share
|
|
Feb 24
2023
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
1,690
-2.39%
|
$238,290
$141.42 P/Share
|
|
Feb 23
2023
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
17,443
+15.27%
|
-
|
|
Feb 23
2023
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,473
-1.82%
|
$216,531
$147.86 P/Share
|
|
Feb 23
2023
|
Sam Samad Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
4,710
+18.77%
|
-
|
|
Feb 23
2023
|
Stephen H Rusckowski Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,059
+5.43%
|
-
|
|
Feb 23
2023
|
Stephen H Rusckowski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,826
-1.74%
|
$856,422
$147.86 P/Share
|
|
Feb 23
2023
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
2,094
+17.45%
|
-
|
|
Feb 23
2023
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
195
-2.44%
|
$28,665
$147.86 P/Share
|
|
Feb 23
2023
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
498
+1.52%
|
-
|
|
Feb 23
2023
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
188
-0.59%
|
$27,636
$147.86 P/Share
|
|
Feb 23
2023
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Grant, award, or other acquisition
|
Direct |
1,919
+15.26%
|
-
|
|
Feb 23
2023
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
245
-2.73%
|
$36,015
$147.86 P/Share
|
|
Feb 23
2023
|
Michael E Prevoznik SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,442
+5.64%
|
-
|
|
Feb 23
2023
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
811
-2.07%
|
$119,217
$147.86 P/Share
|
|
Feb 23
2023
|
Mark E Delaney SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,919
+34.46%
|
-
|
|
Feb 23
2023
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Grant, award, or other acquisition
|
Direct |
3,838
+5.16%
|
-
|
|
Feb 23
2023
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
962
-1.42%
|
$141,414
$147.86 P/Share
|
|
Feb 23
2023
|
Mark A Gardner SVP of Molecular Gen & Oncol |
BUY
Grant, award, or other acquisition
|
Direct |
1,919
+39.65%
|
-
|
|
Feb 01
2023
|
Vicky B Gregg Director |
BUY
Small Acquisition
|
Direct |
64
+0.37%
|
$9,344
$146.75 P/Share
|
|
Feb 01
2023
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Small Acquisition
|
Direct |
13
+0.16%
|
$1,898
$146.75 P/Share
|
|
Feb 01
2023
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Small Acquisition
|
Direct |
27
+0.3%
|
$3,942
$146.75 P/Share
|
|
Dec 01
2022
|
Timothy M Ring Director |
SELL
Open market or private sale
|
Direct |
2,025
-7.74%
|
$307,800
$152.5 P/Share
|
|
Dec 01
2022
|
Timothy M Ring Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,025
+3.8%
|
$115,425
$57.56 P/Share
|
|
Nov 28
2022
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
40,765
-20.84%
|
$6,073,985
$149.14 P/Share
|
|
Nov 28
2022
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Exercise of conversion of derivative security
|
Direct |
40,765
+27.31%
|
$3,505,790
$86.63 P/Share
|
|
Nov 01
2022
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
13,980
+14.75%
|
-
|
|
Nov 01
2022
|
Timothy M Ring Director |
SELL
Open market or private sale
|
Direct |
2,000
-7.65%
|
$288,000
$144.06 P/Share
|
|
Nov 01
2022
|
Timothy M Ring Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+2.52%
|
$122,000
$61.34 P/Share
|
|
Oct 26
2022
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Open market or private sale
|
Direct |
15,497
-32.62%
|
$2,247,065
$145.0 P/Share
|
|
Oct 26
2022
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,497
+14.99%
|
$836,838
$54.14 P/Share
|
|
Oct 19
2022
|
Vicky B Gregg Director |
BUY
Small Acquisition
|
Direct |
74
+0.43%
|
$9,398
$127.67 P/Share
|
|
Oct 03
2022
|
Timothy M Ring Director |
SELL
Open market or private sale
|
Direct |
2,000
-7.71%
|
$246,000
$123.39 P/Share
|
|
Oct 03
2022
|
Timothy M Ring Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+7.16%
|
$122,000
$61.23 P/Share
|